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New technologies in the field of vaccinology arise as a necessity for the treatment and control of many diseases. 
Whole virus inactivated vaccines as well as modified live virus ones used against Bovine Herpesvirus-1 (BoHV-1) 
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capability to induce humoral and cellular immune responses. Nevertheless, “naked” DNA induces low immunogenic 
response. Thus, loading of antigen encoding DNA sequences in liposomal formulations targeting dendritic cell 
receptors could be a promising strategy to better activate these antigen presenting cells (APC). In this work, a DNA 
based vaccine encoding the truncated version of BoHV-1 glycoprotein D (pCIgD) was evaluated alone and 
encapsulated in a liposomal formulation containing LPS and decorated with MANα1-2MAN-PEG-DOPE (pCIgD-
Man-L). The vaccinations were performed in mice and bovines. The results showed that the use of pCIgD-Man-L 
enhanced the immune response in both animal models. For humoral immunity, significant differences were achieved 
when total antibody titers and isotypes were assayed in sera.
Regarding cellular immunity, a significant increase in the proliferative response against BoHV1 was detected in 
animals vaccinated with pCIgD-Man-L when compared to the response induced in animals vaccinated with pCIgD. In 
addition, upregulation of CD40 molecules on the surface of bovine dendritic cells (DCs) was observed when cells 
were stimulated and activated with the vaccine formulations. When viral challenge was performed, bovines vaccinated 
with MANα1-2MAN-PEG-DOPE elicited better protection which was evidenced by a lower viral excretion. 
These results demonstrate that the dendritic cell targeting using MANα1-2MAN decorated liposomes can boost the 
immunogenicity resulting in a long-lasting immunity.
Liposomes decorated with MANα1-2MAN-PEG-DOPE were tested for the first time as a DNA vaccine nanovehicle 
in cattle as a preventive treatment against BoHV-1. These results open new perspectives for the design of vaccines for 
the control of bovine rhinotracheitis.
Keywords:  adjuvant, BoHV-1, DNA, DC targeting vaccine, liposome
1. Introduction
Bovine herpesvirus 1 (BoHV-1), an enveloped virus belonging to the alphaherpesvirus subfamily, infects cattle of all 
ages and breeds worldwide (Babiuk et al., 1987; Tikoo et al., 1995). This virus is a pathogen whose infection can 
severely impact in cattle production. It causes a variety of symptoms in cattle including infectious bovine 
rhinotracheitis (IBR), conjunctivitis, abortions and shipping fever, which is a complicated infection of the upper 
respiratory tract (Jones, 2003). The pathogenesis is responsible for considerable economic losses due to decreased 
milk production, weight loss and abortion and has been recognized as an important component of the bovine 
respiratory complex.
BoHV-1 initiates the disorder through immunosuppression that could render the animals more susceptible to 
secondary bacterial infections, leading to pneumonia and occasionally to death. BoHV-1 establishes latency. Latently 
infected animals should always be considered a potential source of infection (Bitsch, 1973), although vaccination can 
considerably reduce the amount of virus excreted following reactivation (Mars et al., 2001).  
In general, there are control programs including the use of conventional inactivated vaccines or attenuated living 
vaccines but there are no specific international programs to eradicate BoHV-1. In Europe, only a small number of 
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of healthy, seropositive animals because they are persistently infected with BoHV-1. In other European countries, a 
strategy to control this virus has been the implementation of vaccinations with live and inactivated gE-deleted BoHV-
1 (van Drunen Littel-van den Hurk, 2006; Romera et al., 2014). In countries where this infection is endemic such as 
Argentina, Brazil and Spain, voluntarily intensive vaccination programs are implemented to reduce the prevalence of 
infected animals.
Vaccination remains one of the most cost-effective strategies to prevent and control the clinical signs and transmission 
of these viruses. Nevertheless, these vaccines have a series of disadvantages for BoHV-1. Although live attenuated 
vaccines confer protection, there is a risk of reversion to virulence, induction of abortions in pregnant cows and re-
excretion of the vaccine strain by immunosuppression of cattle. In the case of inactivated vaccines, there is a lack in 
providing a complete protection and these vaccines are generally poor inducers of cellular immunity (Deshpande et 
al., 2002; Blome et al., 2013; Quattrocchi et al., 2017). 
BoHV-1 uses a variety of mechanisms to elude the host’s immune system. By spreading intracellularly, it can survive 
in the presence of antiviral specific antibodies (Fuller and Lee, 1992; Miethke et al., 1995). For this reason, cytotoxic 
T-lymphocytes (CTL) are critical for the complete viral clearance (Langellotti et al., 2011).
DNA vaccines emerge as an alternative to conventional vaccines. These vaccines have the potential to induce both 
cellular and humoral immune responses against an antigen encoded by recombinant DNA (Kanthesh et al., 2018) and 
are highly specific; the expressed immunizing antigen is subject to the same modifications as in a natural infection 
(Lee et al., 2015) without the risk of pathogenicity due to incompletely inactivated virus or due to reverted attenuated 
virus (Rajčáni et al., 2005). The use of naked DNA vaccines in small animal models possess and adjuvant or 
immunomodulator effect itself (Yamamoto et al., 1992; Krieg et al., 1995) but in large animals the conferred 
protection is inefficient. For this reason, in order to improve and enhance the immune responses there are attempts 
using DNA plasmids formulated with adjuvants and delivery systems (Quattrocchi et al., 2017). 
The aim of this study was to evaluate the immune responses elicited in a mice model and in bovines by a plasmid 
encoding the truncated version of BoHV-1 glycoprotein D (pCIgD) vehicularized in liposomes decorated with a 
ligand that specifically targets dendritic cells (Man-L). The bilayer formulation included LPS as an adjuvant to 
stimulate the immune response. The liposome surface decoration was performed using a patented synthetic molecule 
(Pappalardo et al., 2013), whose specific α1,2Mannobiose ligand has an affinity for DC-SIGN (Feinberg et al., 2007; 
Yamakawa et al., 2008). The MANα1-2MAN-PEG-DOPE derivative was selected because it can target dendritic cells 
(DCs) of various species (Pappalardo et al., 2013) and thus provide selective delivery of different cargoes such as 
antigens and nucleic acids that can be uptaken and processed for presentation in the contexts of MHC-I and II. 
Brucella ovis HS antigen, which contains a short polysaccharide LPS and some OMP proteins, is associated to this 
nanovaccine as an adjuvant (LPS). The formulation of DNA loaded nanovehicles confers advantages such as an 
increased cargoe uptake by antigen presenting cells (APCs), cytokine secretion stimulated by APC or lymphocytes, 
increased cargoe stability and decreased cargoe degradation (Zaman et al., 2013). MANα1-2MAN-PEG-DOPE has 
been proven to specific target mouse and human primary DC cultures in vitro  (Pappalardo et al., 2013). Previous 
studies have demonstrated in vivo the improved delivery of LPS as an antigen to DC by anchoring MANα1-2MAN-
PEG-DOPE on the liposome surface in a nanovaccine formulation and the effectiveness of this DC-targeted 
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DC-targeted liposomes using MANα1-2MAN-PEG-DOPE were for the first time formulated as a DNA nanovaccine 
against BoHV-1 and evaluated in mice and bovines. These results could be useful to design and improve a vaccine for 
the control of IBR.
2. Materials and Methods
2.1 DNA Plasmid generation
The pCI-neo mammalian expression vector (pCIneo) was obtained from Promega (Madison, WI, USA) and the gene 
encoding the truncated version of BoHV-1 glycoprotein D was cloned (pCIgD) by a standard procedure previously 
described (Langellotti et al., 2011). The plasmids were amplified in transformed MAX Efficiency™ DH5α Competent 
E. coli from Invitrogen (Waltham, MA, USA), and purified by anion exchange chromatography using the Plasmid 
Giga Kit purchased from Qiagen (Hilden, NRW, Germany). The integrity and concentration of the plasmids were 
evaluated before and after each vaccine formulation where restriction digests and 260/280 absorbance ratios were 
analyzed.
2.2 Liposome formulation
A lipid film was prepared by rotary evaporation from a mixture of phosphatidylcholine (PC), cholesterol (Chol), 1,2-
dioleoyl-3-trimethylammonium-propane (DOTAP), Brucella ovis HS extract (LPS), and the α1,2-Mannobiose-
PEG2kDa-DOPE derivative (Manα) (Pappalardo et al., 2013) in chloroform. PC, Chol and DOTAP were purchased at 
Avanti Polar Lipids (Alabaster, AL, USA). The B. ovis HS extract was kindly provided by Mgtr. Carlos Robles 
(Robles, 2009). The lipid film was rehydrated for 30 minutes in sterile normal saline (0.9% NaCl), pH 7.4, at a PC 
concentration of 1.2 mg/mL (mice vaccines) or 4.8 mg/mL (bovine vaccines) in the final suspension and then vortexed 
for 5 minutes. The liposomes were prepared by extrusion of the suspension through a 200 nm pore Whatman® 
Nucleopore® Polycarbonate membrane using an Avanti Polar Lipids Mini Extruder™.
During liposome formulation and extrusion, the combination of all components forming the liposomal suspension, is 
passed through the 200nm pore polycarbonate filter which will generate a uniform population of liposomes. The 
liposomes containing MANα1-2MAN-PEG-DOPE were extensively characterized (Pappalardo et al., 2013)  and the 
average size is around 100nm, when extruded through a 200nm filter. All lipids remain in the lipid bilayer, including 
the LPS. The spikes of PEG with the dimannose ends will protrude outside the liposome core. The DNA is entrapped 
around the outer bilayer by the effect of the cationic DOTAP -which strongly binds the anionic plasmid DNA-. The 
plasmids then are attached to the outer surface and covered/protected by the PEG spikes that protrude further (that is 
why liposomes with PEG are also known as stealth liposomes).
For mice vaccines: formulation of Man-L had PC:Chol:DOTAP:LPS:Manα with a 60:30:10:4.3:2 molar ratio [2.13 
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For bovine vaccines: formulation of Man-L had PC:Chol:DOTAP:LPS:Manα with a 60:30:30:4.3:2 molar ratio [9.96 
mg/mL total lipids]. These were incubated ON with plasmids, resulting in a final dose of 600 µg DNA/1500 µL 
liposomes. “Bovine vaccine” was formulated with a higher ratio of DOTAP with respect to “mice vaccine” to increase 
liposome stability due to the higher concentration of lipids in medium.
2.3 Vaccine formulations and animal treatment
Adjuvanted PC:Chol:DOTAP:LPS:Manα liposome (Man-L) was included as follows. 
In mice: vaccines were formulated using a 15 µg dose of pCIgD according to previous dose–response results 
(Langellotti et al., 2011) or pCIneo as negative control. Groups of BALB/c (n=5) were intradermally (i.d.) inoculated 
at 0 and 20 days with 15 µg /0.3 mL of pCIgD or pCIneo alone; 15 µg /0.3 ml of pCIgD-Man-L or pCIneo-Man-L. 
In bovines: a dose of 600 µg pCIgD was chosen based on a dose–response curve (data not shown). Seronegative 
bovines to BoHV-1 (1–2 years old) were vaccinated i.d. in the back of the ear with 600 µg/1,5 mL (distributed in five 
sites) of pCIgD (n = 5), pCIgD-Man-L (n = 5) and pCIneo as negative control (n = 4). Bovines were vaccinated at 0, 
30 and 60 days. 
2.4 Enzyme-linked immunosorbent assay for detection of anti-BoHV-1 antibodies
Before each animal vaccination, sera were tested by anti BoHV-1 enzyme-linked immunosorbent assay (ELISA). 
Briefly, Immulon 1B polystyrene microtiter plates from Thermo Fisher Scientific Inc. (Waltham, MA, USA) were 
coated with inactivated BoHV-1 (iBoHV-1) Los Angeles strain (1/300) in 0.1 M carbonate-bicarbonate buffer, pH 9.6 
and incubated overnight (ON) at 4°C. Plates were blocked with PBS 0.05% Tween 20 (PBST) containing 1% 
ovalbumin (PBST-OVA). Serial dilutions of mice or bovines sera were prepared in PBST-OVA and dispensed in 50 
µL/well. Plates were washed three times with PBST-OVA and incubated with anti-mouse or anti-bovine IgG 
peroxidase conjugate from KPL (Gaithersburg, MD, USA) respectively for 1 h at 37°C. After extensive washing with 
PBST, ortho-phenylene-diamine (1,2-benzenediamine) dihydrochloride -OPD- (Sigma-Aldrich, St. Louis, MO, USA) 
and H2SO4 were added as substrate. To measure the absorbance at 492 nm a Multiskan MS/352 microplate reader was 
used (Labsystems Oy, Helsinki, Finland). The cut-off was established using the negative sera mean at A492 plus 2 
standard deviations (SD). Titers were calculated as the log10 of the reciprocal value of the highest dilution that had an 
OD above the cut-off level from animals vaccinated with pCIneo. 
2.5 Immunoglobulin isotyping ELISA 
Isotype profile by indirect ELISA was evaluated to determine the IgG1, IgG2a, IgG2b and IgG3 subtypes in 
immunized mice at 40 days post vaccination (dpv). The IgG1 and IgG2 isotype titer from sera of immunized bovines 
was determined at 90 dpv, and the IgA from nasal swabs was determined at 6 days post challenge (dpc). Briefly, 
Microlon polystyrene microtiter plates from Greiner Bio-One GmbH (Kremsmünster, OÖ, Austria) were coated with 
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biotinylated goat anti-mouse IgG1, IgG2a, IgG2b and IgG3 from Caltag Laboratories (San Francisco, CA, USA). 
After a 60 minutes incubation, plates were washed with PBST and a dilution of streptavidin/alkaline phosphatase 
(Sigma-Aldrich) was added to each well. The 1/50 sera dilution OD readings at A492 nm corresponding to IgG1, 
IgG2a, IgG2b, and IgG3 were recorded.  
For isotype detection in bovines, the ELISA described in chapter 2.4 with modifications was used. An anti-bovine 
IgG1, IgG2, or IgA mouse monoclonal antibodies were used (kindly provided by Dr. S. Srikumaran from the 
University of Nebraska, USA). An incubation with horse radish peroxidase (HRP) conjugated anti-mouse Ig was 
followed. Finally, the reaction was visualized, and the cut-off for IgG1 and IgG2was established as described before. 
The results for IgA 1/2 dilution in nasal swabs were expressed as OD at A492 nm. 
2.6 Afferent lymph dendritic cell (ALDC) stimulation in vitro
The extraction of ALDCs from bovines was performed as previously described (Hope et al., 2006) by cannulation of 
pseudo afferent lymph vessels. Dendritic cells were incubated in RPMI 1640 medium supplemented with 10% fetal 
bovine serum from Gibco (Thermo Fisher Scientific Inc.), 1% penicillin-streptomycin-amphotericin B antibiotic-
antimycotic solution (Sigma-Aldrich) and 50 mM 2-mercaptoethanol (RPMI 10% FBS). Treatments were mock 
stimulated or 1 μg/mL pCIgD, pCIgD-Man-L vaccine formulations or plasmid free α1,2-Mannobiose-PEG2kDa-DOPE 
decorated liposome (Man-L) with (+) or without (-) LPS from Brucella ovis. A direct cell surface staining was 
performed after a 16 h incubation with a monoclonal antibody DEC205-FITC from AbD Serotec (Kidlington, 
Oxfordshire, UK). Indirect surface staining was performed using monoclonal antibody anti-CD40 (AbD Serotec), and 
anti-mouse IgG PE conjugated from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA, USA). Finally, 
fixed cells (0.2% paraformaldehyde) were acquired using a Becton Dickinson FACScalibur flow cytometer and 
CellQuest software (San Jose, CA, USA).
2.7 Mouse splenocytes and bovine peripheral blood mononuclear cell (PBMC) isolation 
Splenocytes from immunized mice were collected at 120 dpv, stimulated in vitro with iBoHV-1, and assayed for 
antigen-specific proliferation. Splenocytes were obtained by gentle homogenization of spleens in RPMI 10% FBS, 
and counted using Turk method. Venipuncture was performed to collect bovine blood samples using syringes 
containing sodium citrate as an anticoagulant. Ficoll-Paque™ PLUS (density 1.077 g/mL) from GE Healthcare 
(Chicago, IL, USA) was used as described previously (Romera et al., 2000) to isolate PBMCs by centrifugation. Cells 
were counted using Trypan blue. 
2.8 Lymphoproliferation Assay
Carboxyfluorescein diacetate succinimidyl ester (CFSE) 3 µM was incubated with the cell cultures for 30 min at 37°C 
to label splenocytes and PBMCs suspensions. Later, cells were washed and resuspended in RPMI 10% FBS as 
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well were added to a 96-well U-bottom plate. In each well, 100 µL of complete medium containing iBoHV-1 
(MOI=1), concanavalin A (ConA) (Sigma-Aldrich) as positive proliferation control, or medium as negative control 
were added. After cell incubation for 4 days (mice) or 5 days (bovines) at 37°C in 5% CO2 atmosphere, cells were 
harvested and fixed and the proliferation was analyzed by flow cytometry as described in chapter 2.6. 
2.9 Viral challenge in bovines
At 90 dpv, bovines were challenged by aerosol exposition as described previously (Romera et al., 2014; Quattrocchi et 
al., 2017) with 5 mL of 1x106.81 TCID50/mL BoHV-1 Los Angeles strain in each nostril. Animals were clinically 
examined at 0, 3, 5, 6, 7, 8 and 12 dpc. Rhinitis severity was scored after viral challenge as follows:  0 = absence of 
rhinitis ; 1 = slight serous rhinitis with or without mild serous conjunctivitis;  2 = severely serous rhinitis;  3 = 
seromucous with moderate or severe conjunctivitis; 4 = mucopurulent rhinitis with or without conjunctivitis (Romera 
et al., 2014).
Samples for viral excretion were obtained at the same days described above by inserting tampons into each nostril as 
nasal swabs. These tampons were dipped in Minimal Essential Medium (MEM) which contained 5,000 IU/mL 
penicillin, 2,500 µg/mL streptomycin, and 10 µg/mL amphotericin B. These samples were inoculated onto MDBK 
cell monolayers in serial dilutions, and checked for cytopathic effect (cpe). An end point dilution method was 
performed to obtain virus titers (Reed and Muench, 1938).
2.10 Statistical analysis
ANOVA and Bonferroni post-hoc tests were performed to evaluate if the differences were significant, using the 
InfoStat software. Differences between two means were analyzed using Student’s t-test. A value of P < 0.05 was 
considered as statistical significant. 
3. Results
3.1 pCIgD-Man-L increased specific BoHV-1 antibodies in mouse
In order to study the humoral immune response induced by pCIgD-Man-L vaccine, an ELISA test to detect anti-
BoHV-1 antibodies was used. Vaccines pCIgD and pCIgD-Man-L were capable to induce specific antibodies at 20 
and 40 days after administration, but the formulation with liposomes improved notably the IgG titer with respect to 
pCIgD (p<0.01, p<0.05 respectively). In addition, it was possible to detect titers at 120 days. For pCIgD-Man-L, 
antibody titer levels remained higher (p<0.001) with respect to those observed on the pCIgD treated group, where the 
titer declined (Fig.1a).
When the profile of antibody isotypes was analyzed, a marked difference between the group treated with pCIgD-Man-
L and the group treated with pCIgD alone was observed. The group treated with pCIgD-Man-L had elevated IgG1 
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3.2 pCIgD-Man-L induces viral specific proliferation of lymphocytes in mice 
A lymphoproliferative assay was performed to study the cellular immune response against the viral antigen. After 
splenocyte collection from mice, the cells were stimulated in vitro with iBoHV-1. As a result, the percentages of 
specific lymphoproliferation was higher in pCIgD-Man-L group (p<0.05) in comparison with the pCIgD group 
(Fig.2). Taken together, these results indicate that pCIgD vaccine formulated with liposome Man-L could induce a 
higher humoral and cellular response against BoHV-1 in mice. Therefore, this formulation was further tested in a trial 
in bovines, the natural host species. 
3.3 pCIgD-Man-L increased specific BoHV-1 antibodies titers in bovines
The animals were vaccinated at 0, 30 and 60 days. Regarding antibody kinetics, pCIgD and pCIgD-Man-L were able 
to induce specific anti-BoHV-1 antibody levels (Fig.3a). However, significant differences in pCIgD-Man-L at 60 dpv 
(p<0.05) were found compared with pCIgD group. After viral challenge (90 dpv) all animals seroconverted (data not 
shown). 
In addition, ELISA isotype titers at 90 dpv against BoHV-1 were analyzed (Fig. 3b). Interestingly, there were 
significant differences in IgG1 (p<0.001) for the pCIgD and pCIgD-Man-L group versus pCIneo, but in IgG2 
difference was observed only for pCIgD-Man-L (p<0.05) with respect to the pCIneo group. 
No significant differences among groups were found when neutralizing antibodies were measured; however, a trend of 
increasing neutralizing antibodies was observed in pCIgD-Man-L over pCIgD treated groups (data not shown).
Antibodies in nasal swabs were also evaluated. It is reported that the presence of antibodies in nasal mucosa confer 
protection against respiratory viral penetration. IgA isotype anti-BoHV-1 level in nasal swabs at 6 days post challenge 
(dpc) was evaluated (Fig. 3c). The results showed that the IgA titer in swabs of the pCIgD-Man-L treated group was 
significantly different compared with pCIneo treated group (p<0.05). 
3.4 pCIgD and Man-L modulate Dendritic Cells by Activation in vitro
The key initiators of antiviral responses are dendritic cells, the major antigen presenting cell (APC) in the immune 
system (Ludewig et al., 2000). They endocytose, process and present antigens to naive T cells and act as messengers 
between the adaptive and innate immune responses. Afferent lymph dendritic cells (ALDCs) from bovines were used 
to elucidate if DNA alone or with loaded targeted liposomes were able to activate dendritic cells. ALDCs were 
incubated with vaccines pCIgD, pCIgD-Man-L (with or without LPS from Brucella ovis) or Man-L alone (with or 
without LPS from Brucella ovis) in vitro. CD40 surface molecules were significantly upregulated with respect to 
mock for pCIgD (p<0.01), pCIgD-Man-L with (p<0.05) and without LPS (p<0.01). Also, CD40 was upregulated 
when treated with Man-L with LPS (p<0.001) but not with Man-L without LPS. These results indicate that pCIgD 
alone and liposomes including LPS can activate dendritic cells (Fig.4).
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Lymphoproliferation was evaluated at 12 dpc in PBMCs after in vitro stimulation with inactivated BoHV-1. The 
results showed that pCIgD-Man-L treated group underwent the highest degree of proliferation with respect pCIneo 
(p<0.01) and pCIgD group (p<0.05) (Fig. 5). This result indicates that the liposomes possess a remarkable “adjuvant” 
effect and are capable of enhancing the cellular immune response elicited by pCIgD in bovines. 
3.6 Viral excretion is decreased in pCIgD-Man-L group
Bovines were challenged at 90 dpv via aerosol with BoHV-1 Los Angeles strain. In order to measure the viral 
excretion after virus challenge trial, nasal secretions were obtained. 
Here it is shown that pCIgD and pCIgD-Man-L treatments were capable to reduce the viral excretion compared with 
the pCIneo treated group but the bovines that received the pCIgD-Man-L nanovaccine presented a markedly reduction 
of the viral excretion at 5 dpc compared with pCIneo group (p<0.01). This phenomenon was not observed in the 
pCIgD group (Fig 6). In addition, these results were analyzed as the area under curve (AUC) of the viral titer. In this 
way, AUC of the viral titers in animals treated with pCIgD-Man-L was the lowest with respect to the other groups. 
3.7 pCIgD and pCIgD-Man-L presented similar clinical score
Clinical score was obtained by measuring the symptoms acquired by the animals after the viral challenge and was 
established according with a degree of rhinitis ranging from 0 to 4 in ascending order of severity as we described in 
chapter 2.9. Therefore, the animals vaccinated with pCIgD and pCIgD-Man-L had a lower clinical score and there 
were significant differences compared with pCIneo group (p<0.05) at 6 dpc for pCIgD and at 7 dpc for pCIgD-Man-L 
(p<0.05) but there were no significant differences between them (Fig. 7). Clinical score AUC was analyzed and again 
pCIgD-Man-L treated animals had the lowest level with respect to the other groups. 
4. Discussion
DNA vaccines have taken great interest in the field of vaccinology because of their simplicity, safety, stability, and 
versatility for development (Kanthesh et al., 2018). Previous studies with these vaccines have shown to induce good 
levels of humoral and cellular immunity in different species models depending on the type of encoded antigen, route 
of administration and promoter efficiency (Huang et al., 2005). The glycoprotein D is involved in virus penetration 
and has been considered the major target in vaccine development against bovine and human herpesvirus. A big issue 
of DNA vaccines is the low immunogenicity due to difficulties in delivering DNA plasmids into the host cells for 
further synthesis of the encoded antigenic protein (Suschak et al., 2017). Here, the use of suitable delivery systems 
and specific molecular activators can be combined to generate adjuvants that can help to improve the efficiency of 
DNA vaccines. In the search to set up a vaccine that generates both types of immunity against BoHV-1, we 
investigated DNA vaccines using a DNA sequence encoding for the truncated version of BoHV-1 D glycoprotein 
(pCIgD). Our previous studies using the same DNA plasmid combined with chemical adjuvants in mice provided 









This article is protected by copyright. All rights reserved
cattle with a subsequent viral challenge showed the protection was only partial (Quattrocchi et al., 2017) which 
prompted us to further search for new formulation strategies.
In this context, we have designed a DNA nanovaccine using liposomes decorated with mannose molecules for DC 
targeting which is expected to enhance the transfection efficiency in DCs, including LPS in the formulation as a 
molecular adjuvant to promote DC maturation and immunity through TLR activation. This will result in the ability of 
the liposomes to selectively target the DC-SIGN receptor in DCs and deliver its cargoe. Liposomes were selected 
because they represent a self-assembling carrier that allow to combine different functional components on their 
surface resulting in a cooperative adjuvant effect. In addition, liposomes protect DNA from deoxyribonuclease attack 
(Gregoriadis et al., 2002). 
The intradermal inoculation is one of the best performing administration strategies to deliver a DNA vaccines 
(Zonouzi et al., 2016). The rational for this is that the skin possess associated lymphoid tissue, including Langerhans 
cells, dendritic cells, keratinocytes and other immune cells. Here, we inoculated animals by the intradermal route, and 
we observed an improved humoral and cellular immune response. In agreement with evidences that truncated 
glycoprotein D can induce good levels of humoral immune response (Van Drunen Littel-van den Hurk et al., 1998; 
Lewis et al., 1999; Huang et al., 2005) we obtained antibody titers upon administration of pCIgD which was 
significantly increased when the plasmid encoding for the truncated glycoprotein D was formulated with a DC-
targeted liposome including LPS as adjuvant (pCIgD-Man-L). It is interesting to note that although no new 
inoculation was made after 40 dpv in mice, there were high levels of antibody even at 120 dpv with pCIgD-Man-L, 
but this phenomenon was not observed with pCIgD alone. This can be attributed to the local depot effect, and the 
selective delivery and activation capacities of the liposomes combined with LPS from B. ovis (Fredriksen and Grip, 
2012) thus enhancing and prolonging the exposure of the immune cells to the antigen which results in a specific 
immune response and long lasting immunity. When isotype antibodies were analyzed, the specific effect of the 
liposomal vaccine resulted in the increase of the IgG1 levels and the profile of IgG2a, IgG2b when compared with the 
pCIgD group, where the levels of antibodies were significantly lower. Notably IgG2a is an isotype that is crucial for 
the defense against viruses. Previous works have shown that IgG2a antibodies are produced in mice upon viral 
infections (Coutelier et al., 1991) and there are also triggered when DNA vaccines are administered for immunizations 
(Raz et al., 1996) as a result of T helper 1 cell involvement. This isotype is efficient for complement fixation and acts 
as an opsonizing agent. It is reported that IFNγ can stimulate the IgG2a production both by in vitro and in vivo by 
activating the B lymphocytes. The increase of IgG2a in the animals treated with our free DNA plasmid suggests that 
the gD plasmid could be internalized by DCs and that the interaction between DCs-B cells may take place according 
to CD40:CD40L dependent manner (Bao et al., 2014). The B cell switching was confirmed by the presence of the 
IgG2a isotype in sera of mice and by the polarization of the T CD4+ cells response to a Th1/Th2 profile. 
The immune system fast response to a viral infection confirms the cellular memory to the viral antigens. This could 
prove that the viral antigens were previously processed by the host and CD4+/CD8+ memory lymphocytes were 
generated. In this work, we observed that splenocytes in culture from mice immunized with gD plasmids were able to 
lymphoproliferate against inactivated BoHV-1. Moreover, it is important to highlight that these animals got their last 
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lymphoproliferate in the pCIgD-Man-L group was certainly provided by the adjuvant effect of the targeted liposome 
because this was not observed with the DNA plasmid administered alone.
We then tested the novel liposome based nanovaccine in a field trial in cattle. When we assessed BoHV-1 specific 
antibodies in blood the difference was significant between the pCIgD-Man-L immunized group compared to the 
control group. This increase was also observed in the isotype antibody titers. While in the murine model, the 
transcription factors in T helper lymphocytes such as GATA-3 associated with enhanced type 2 cytokine gene 
transcription (IL-4) or T-bet associated to type 1 cytokine (IFNγ) have been widely shown, these factors are not 
evident in bovines (Estes and Brown, 2002). Bovine IL-4 could induce IgG1 while IFNγ  may enhance IgG2 over 
IgG1 (Estes et al., 1995). The results obtained in our study for bovine isotypes elicited by the vaccines, showed  
increasing levels of IgG1-IgG2 for both vaccines when compared to the control, as it was observed in previous tests 
with other DNA vaccines or adjuvants (Arulkanthan et al., 1999; Brown et al., 1999; Quattrocchi et al., 2017). 
However, a significant IgG1:IgG2 ratio increase was observed only for pCIgD-Man-L whereas a significant IgG1 
increase solely occurred in the group vaccinated with pCIgD when compared to the control. 
IgA was assessed from nasal swabs and evaluated 6 days post challenge resulting in higher titer in the pCIgD-Man-L 
treated group with respect to the control pCIgD treated group. Reasonably, the persistence and enhanced exposure to 
glycoprotein D post challenge can be responsible for the expansion of DC-primed cell and IgGs and IgA secreting B 
cell populations as hypothized by Manoj (Manoj et al., 2004). 
CD40 is a co-stimulatory cytokine for  various types of cells including B cells, macrophages, non-hematopoietic cells 
and DCs, for which it has an crucial role in immunity development and in activation of the latter cell types (Elgueta et 
al., 2009). DCs are the major antigen presenting cells (APC) and they are crucial mediators between immune innate 
and adaptive responses (Vázquez et al., 2012). When DCs are inactivated, CD40 is expressed constitutively at 
relatively low levels on their surface (Banchereau et al., 1994). Upon  DC cells encounter pathogens, antigens (Kawai 
and Akira, 2007) or apoptotic cells (Ip and Lau, 2004), CD40 expression is up-regulated on their surface and is 
activated. In this work, ALDCs were stimulated and activated after incubation with free DNA plasmid and DNA 
loaded targeted liposomes embedding LPS from Brucella ovis. It is well known that DNA possess CpG domain which 
can be recognized by APCs and trigger their response (Kuwajima et al., 2006). Here, we observed that ALDCs 
incubated with free DNA plasmid showed positive up regulation of CD40 molecule. Also, targeted liposomes alone or 
associated with DNA and functionalized with LPS from Brucella ovis are capable to enhance the expression of CD40 
on the surface of DCs. This result proves that the nanovaccines represent a promising platform that comply the idea 
that an efficient vaccine must target the APCs. Notably, the liposomes formulated without the LPS were not able to 
activate DCs. In this way, the MANα1-2MAN targeting provides a crucial function to selectively target the dendritic 
cells while the LPS address its function as an adjuvant of the cell response.
Since it is well known that cell-mediated immunity is very important for virus clearance upon BoHV-1 and other 
viruses infection, a better protection induced after challenge in animals immunized with targeted DNA loaded 
liposomes was observed. Animals from pCIgD-Man-L treated group had less viral excretion with significant decrease 
of viral titer at 5 dpc respect to control group. Furthermore, induction of cellular immune response was observed at 12 
dpc in pCIgD-Man-L treated group with positive response to viral-specific PBMCs proliferation. The activation of 
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the lymphoproliferative effect in pCIgD-Man-L treated group shows a better immune response, in which memory 
cells became established and were able to recognize the viral antigen more quickly than in pCIgD treated and control 
groups.
Although, the clinical score was similar for the animals vaccinated with free DNA plasmid and those immunized with 
the DNA loaded targeted liposomes, these animals presented less clinical symptoms than the control animals during 
viremia. 
The development of efficient vaccines for BoHV-1 based on selective DNA delivery to DCs using new carriers 
including liposomes may allow better control of virus circulation in livestock. Although this trial as a proof of concept 
demonstrates that animals vaccinated with the engineered liposomal formulation improved humoral and cellular 
response levels, the impact of formulation parameters including vaccine dose and booster/lipid ratio still need to be 
systematically elucidated. Nevertheless, this study opens up perspectives for the generation of a new generation 
vaccine for robust protection of the animals against viral exposure.
To our knowledge, it is the first time that liposomes decorated with MANα1-2MAN-PEG-DOPE as immune targeting 
agent were used in a DNA based vaccine for BoHV-1 immunization and tested in cattle.
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